Abstract:The pan‐cancer analyses of bromodomain containing 9 (BRD9) provided a comprehensive perspective for the development of BRD9‐based targeted therapies for a variety of different cancers. BRD9 may affect cancer progression through different phosphorylation sites or N6‐methyladenosine site modifications. BRD9 could be used as a novel biomarker for diagnosis of multiple cancer types. Our functional study of BRD9 showed interaction with SMARCD1. Knockdown of BRD9 could inhibit the progression of lung and colon cancers through the Wnt/β‐catenin signalling pathway. Background Mutations in one or more genes responsible for encoding subunits within the SWItch/Sucrose Non‐Fermentable (SWI/SNF) chromatin‐remodelling complexes are found in approximately 25% of cancer patients. Bromodomain containing 9 (BRD9) is a more recently identified protein coding gene, which can encode SWI/SNF chromatin‐remodelling complexes subunits. Although initial evaluations of the potential of BRD9‐based targeted therapy have been explored in the clinical application of a small number of cancer types, more detailed study of the diagnostic and prognostic potential, as well as the detailed biological mechanism of BRD9 remains unreported. Methods We used various bioinformatics tools to generate a comprehensive, pan‐cancer analyses of BRD9 expression in multiple disease types described in The Cancer Genome Atlas (TCGA). Experimental validation was conducted in tissue microarrays and cell lines derived from lung and colon cancers. Results Our study revealed that BRD9 exhibited elevated expression in a wide range of tumours. Analysis of survival data and DNA methylation for BRD9 indicated distinct conclusions for multiple tumours. mRNA splicing and molecular binding were involved in the functional mechanism of BRD9. BRD9 may affect cancer progression through different phosphorylation sites or N6‐methyladenosine site modifications. BRD9 could potentially serve as a novel biomarker for diagnosing different cancer types, especially could accurately forecast the prognosis of melanoma patients receiving anti‐programmed cell death 1 immunotherapy. BRD9 has the potential to serve as a therapeutic target, when pairing with etoposide in patients with melanoma. The BRD9/SMARCD1 axis exhibited promising discriminative performance in forecasting the prognosis of patients afflicted with liver hepatocellular carcinoma (LIHC) and mesothelioma. Additionally, this axis appears to potentially influence the immune response in LIHC by regulating the programmed death‐ligand 1 immune checkpoint. For experimental validation, high expression levels of BRD9 were observed in tumour tissue samples from both lung and colon cancer patients. Knocking down BRD9 led to the inhibition of lung and colon cancer development, likely via the Wnt/β‐catenin signalling pathway. Conclusions These pan‐cancer study revealed the diagnostic and prognostic potential, along with the biological mechanism of BRD9 as a novel therapeutic target in human tumours.

BRD9 promotes the progression of gallbladder cancer via CST1 upregulation and interaction with FOXP1 through the PI3K/AKT pathway and represents a therapeutic target

BRD9 promotes the progression of gallbladder cancer via CST1 upregulation and interaction with FOXP1 through the PI3K/AKT pathway and represents a therapeutic target

Pan‐cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours

Bromodomain-containing protein 9 promotes hepatocellular carcinoma progression via activating the Wnt/β-catenin signaling pathway

Bromodomain-containing protein 9 activates proliferation and epithelial-mesenchymal transition of colorectal cancer via the estrogen pathway in vivo and in vitro

Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway

Targeting BRD9 for Cancer Treatment: A New Strategy

BRD9 is an Essential Regulator of Glycolysis That Creates an Epigenetic Vulnerability in Colon Adenocarcinoma

Bromodomain-containing Protein 9 Promotes the Growth and Metastasis of Human Hepatocellular Carcinoma by Activating the TUFT1/AKT Pathway

BRD9 controls the oxytocin signaling pathway in gastric cancer via CANA2D4, CALML6, GNAO1, and KCNJ5

Bromodomain‐containing Protein 9 is a Prognostic Biomarker Associated with Immune Infiltrates and Promotes Tumor Malignancy Through Activating Notch Signaling Pathway in Negative HIF‐2α Clear Cell Renal Cell Carcinoma

Potential Roles of PBRM1 on Immune Infiltration in Cholangiocarcinoma.

FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis

BRD7, a novel bromodomain gene, inhibits G1-S progression by transcriptionally regulating some important molecules involved in ras/MEK/ERK and Rb/E2F pathways.

BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo

SIRT7: A potential prognostic marker and therapeutic target in gallbladder cancer

BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network

BRD7, a Novel Bromodomain Gene, Inhibits G1–S Progression by Transcriptionally Regulating Some Important Molecules Involved in Ras/mek/erk and Rb/E2F Pathways

BRD4/8/9 are prognostic biomarkers and associated with immune infiltrates in hepatocellular carcinoma

BRG1 promotes progression of B-cell acute lymphoblastic leukemia by disrupting PPP2R1A transcription

IGF2BP3 promotes progression of gallbladder carcinoma by stabilizing KLK5 mRNA in N6-methyladenosine-dependent binding